View ValuationEMS-CHEMIE HOLDING 将来の成長Future 基準チェック /26EMS-CHEMIE HOLDING利益と収益がそれぞれ年間6%と3.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に27.6% 5.6%なると予測されています。主要情報6.0%収益成長率5.55%EPS成長率Chemicals 収益成長9.6%収益成長率3.2%将来の株主資本利益率27.59%アナリストカバレッジGood最終更新日23 Jul 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €845, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 13x in the Chemicals industry in Italy. Total returns to shareholders of 28% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €656 per share.お知らせ • Jul 13EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026, at 10:30 W. Europe Standard Time.Buy Or Sell Opportunity • Jun 30Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to €770. The fair value is estimated to be €637, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.8% per annum. Earnings are also forecast to grow by 5.2% per annum over the same time period.New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Jun 09Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 15% to €775. The fair value is estimated to be €645, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings are also forecast to grow by 4.7% per annum over the same time period.Buy Or Sell Opportunity • May 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to €765. The fair value is estimated to be €633, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.6% per annum. Earnings are also forecast to grow by 4.5% per annum over the same time period.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Feb 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 15% to €690. The fair value is estimated to be €569, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last 3 years. Earnings per share has declined by 3.6%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings are also forecast to grow by 4.9% per annum over the same time period.Reported Earnings • Feb 08Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024)Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Italy.お知らせ • Feb 05+ 1 more updateEMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Final Results on Jul 10, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 final results on Jul 10, 2026Board Change • Feb 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 06EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026Board Change • Sep 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Aug 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 15EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025, at 10:30 W. Europe Standard Time.お知らせ • Jul 13EMS-CHEMIE HOLDING AG announces Annual dividend, payable on August 14, 2025EMS-CHEMIE HOLDING AG announced Annual dividend of CHF 13.9500 per share payable on August 14, 2025, ex-date on August 12, 2025 and record date on August 13, 2025.業績と収益の成長予測BIT:1EMSN - アナリストの将来予測と過去の財務データ ( )CHF Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,164559509580612/31/20272,069533490565712/31/20261,976504492548712/31/20251,969467506534N/A9/30/20251,996464476507N/A6/30/20252,024462445479N/A3/31/20252,057461446480N/A12/31/20242,091461448480N/A9/30/20242,104461473505N/A6/30/20242,117462499529N/A3/31/20242,165460513553N/A12/31/20232,213458527576N/A9/30/20232,294475456523N/A6/30/20232,374493385469N/A3/31/20232,425512328418N/A12/31/20222,475532272366N/A9/30/20222,438545297385N/A6/30/20222,401557322403N/A3/31/20222,342554380461N/A12/31/20212,283550438518N/A9/30/20212,218536443512N/A6/30/20212,154521447507N/A3/31/20211,994478435489N/A12/31/20201,833434423472N/A9/30/20201,867444443497N/A6/30/20201,900453462522N/A3/31/20202,055490476537N/A12/31/20192,209527489552N/A9/30/20192,257527N/A541N/A6/30/20192,305527N/A529N/A3/31/20192,327523N/A514N/A12/31/20182,350520N/A499N/A9/30/20182,330517N/A509N/A6/30/20182,310515N/A520N/A3/31/20182,243498N/A481N/A12/31/20172,177482N/A443N/A9/30/20172,126471N/A446N/A6/30/20172,076461N/A449N/A3/31/20172,044455N/A468N/A12/31/20162,012449N/A486N/A9/30/20161,987428N/A467N/A6/30/20161,962407N/A449N/A3/31/20161,947392N/A429N/A12/31/20151,932376N/A410N/A9/30/20151,944360N/A427N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1EMSNの予測収益成長率 (年間6% ) は 貯蓄率 ( 3.3% ) を上回っています。収益対市場: 1EMSNの収益 ( 6% ) Italian市場 ( 11.1% ) よりも低い成長が予測されています。高成長収益: 1EMSNの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 1EMSNの収益 ( 3.2% ) Italian市場 ( 6.3% ) よりも低い成長が予測されています。高い収益成長: 1EMSNの収益 ( 3.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1EMSNの 自己資本利益率 は、3年後には高くなると予測されています ( 27.6 %)成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/26 19:34終値2026/07/24 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EMS-CHEMIE HOLDING AG 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Konstantin WiechertBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchAdrien TamagnoBerenberg11 その他のアナリストを表示
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €845, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 13x in the Chemicals industry in Italy. Total returns to shareholders of 28% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €656 per share.
お知らせ • Jul 13EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026, at 10:30 W. Europe Standard Time.
Buy Or Sell Opportunity • Jun 30Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to €770. The fair value is estimated to be €637, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.8% per annum. Earnings are also forecast to grow by 5.2% per annum over the same time period.
New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Jun 09Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 15% to €775. The fair value is estimated to be €645, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings are also forecast to grow by 4.7% per annum over the same time period.
Buy Or Sell Opportunity • May 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to €765. The fair value is estimated to be €633, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.6% per annum. Earnings are also forecast to grow by 4.5% per annum over the same time period.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Feb 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 15% to €690. The fair value is estimated to be €569, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last 3 years. Earnings per share has declined by 3.6%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings are also forecast to grow by 4.9% per annum over the same time period.
Reported Earnings • Feb 08Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024)Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Italy.
お知らせ • Feb 05+ 1 more updateEMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Final Results on Jul 10, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 final results on Jul 10, 2026
Board Change • Feb 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 06EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026
Board Change • Sep 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Aug 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 15EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025, at 10:30 W. Europe Standard Time.
お知らせ • Jul 13EMS-CHEMIE HOLDING AG announces Annual dividend, payable on August 14, 2025EMS-CHEMIE HOLDING AG announced Annual dividend of CHF 13.9500 per share payable on August 14, 2025, ex-date on August 12, 2025 and record date on August 13, 2025.